دورية أكاديمية
Management of Gastric Neuroendocrine Tumors: A Review.
| العنوان: | Management of Gastric Neuroendocrine Tumors: A Review. |
|---|---|
| المؤلفون: | Sok C; Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA., Ajay PS; Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA., Tsagkalidis V; Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kooby DA; Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA., Shah MM; Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA. mihir.m.shah@emory.edu. |
| المصدر: | Annals of surgical oncology [Ann Surg Oncol] 2024 Mar; Vol. 31 (3), pp. 1509-1518. Date of Electronic Publication: 2023 Dec 07. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005- : New York, NY : Springer Original Publication: New York, NY : Raven Press, c1994- |
| مواضيع طبية MeSH: | Neuroendocrine Tumors*/pathology , Zollinger-Ellison Syndrome*/pathology , Pancreatic Neoplasms*/surgery , Stomach Neoplasms*/pathology, Humans ; Gastrins ; Gastric Mucosa/pathology |
| مستخلص: | Gastric neuroendocrine tumors (G-NET) are rare tumors arising from enterochromaffin-like cells of the gastric mucosa. They belong to a larger group called gastroenteropancreatic neuroendocrine tumors and are classified as low, intermediate, or high-grade tumors based on their proliferative indices. They are further categorized into three subtypes based on their morphologic characteristics, pathogenesis, and behavior. Types 1 and 2 tumors are characterized by elevated serum gastrin and are usually multifocal. They typically occur in the setting of atrophic gastritis or MEN1/Zollinger Ellison syndrome, respectively. Type 2 tumors are associated with the most symptoms, such as abdominal pain and diarrhea. Type 3 tumors are associated with normal serum gastrin, are usually solitary, and occur sporadically. This type has the most aggressive phenotype and metastatic potential. Treatment and prognosis for G-NET is dependent on their type, size, and stage. Type 1 has the best prognosis, and Type 3 has the worst. This review discusses the presentation, workup, and surgical management of these tumors. (© 2023. Society of Surgical Oncology.) |
| التعليقات: | Comment in: Ann Surg Oncol. 2024 Mar;31(3):1519-1520. (PMID: 38123732) |
| References: | World J Gastroenterol. 2021 Sep 21;27(35):5890-5907. (PMID: 34629807) Dig Surg. 2021;38(1):38-45. (PMID: 33260173) Oncologist. 2022 Apr 5;27(4):299-306. (PMID: 35380711) J Neuroendocrinol. 2021 May;33(5):e12967. (PMID: 33769624) Ann Surg Oncol. 2021 Dec;28(13):8838-8846. (PMID: 34120268) Aliment Pharmacol Ther. 2006 Nov 1;24(9):1305-20. (PMID: 17059512) Oncologist. 2016 Oct;21(10):1191-1199. (PMID: 27401895) Mol Clin Oncol. 2021 Jan;14(1):20. (PMID: 33363730) Histopathology. 2020 Jan;76(2):182-188. (PMID: 31433515) BMC Cancer. 2016 Jan 22;16:36. (PMID: 26801624) PET Clin. 2014 Jan;9(1):43-55. (PMID: 25029933) Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1219-27. (PMID: 17260141) Eur J Endocrinol. 2004 Jul;151(1):15-27. (PMID: 15248818) Gastroenterology. 2002 Jul;123(1):68-85. (PMID: 12105835) Ann Surg Oncol. 2009 Nov;16(11):3154-60. (PMID: 19727959) Surgery. 2021 Jun;169(6):1417-1423. (PMID: 33637345) PLoS One. 2013 Oct 01;8(10):e76462. (PMID: 24098507) AJR Am J Roentgenol. 2014 Sep;203(3):W260-6. (PMID: 25148182) Cancer Manag Res. 2021 Nov 03;13:8273-8279. (PMID: 34764690) World J Gastrointest Oncol. 2020 Aug 15;12(8):850-856. (PMID: 32879663) Ann Oncol. 2020 Jul;31(7):844-860. (PMID: 32272208) World J Gastrointest Oncol. 2020 Aug 15;12(8):791-807. (PMID: 32879660) J Clin Oncol. 2015 Jun 1;33(16):1855-63. (PMID: 25918282) World J Surg Oncol. 2022 May 24;20(1):165. (PMID: 35610656) Aliment Pharmacol Ther. 2014 May;39(10):1071-84. (PMID: 24628514) Am J Gastroenterol. 1995 Mar;90(3):338-52. (PMID: 7872269) Am J Surg. 2019 May;217(5):937-942. (PMID: 30686481) Cancer. 1975 Aug;36(2):560-9. (PMID: 1157019) Med Sci Monit. 2004 Jun;10 Suppl 3:9-16. (PMID: 16538192) Pancreas. 2010 Aug;39(6):735-52. (PMID: 20664472) Surg Case Rep. 2021 Jan 12;7(1):15. (PMID: 33433761) Aliment Pharmacol Ther. 2011 Jun;33(12):1361-9. (PMID: 21492197) Curr Treat Options Gastroenterol. 2007 Apr;10(2):123-33. (PMID: 17391627) Clin Endocrinol (Oxf). 2019 Oct;91(4):534-543. (PMID: 31254407) Semin Oncol. 2013 Feb;40(1):100-8. (PMID: 23391117) Clin Cancer Res. 2016 Feb 15;22(4):1011-7. (PMID: 26482044) Endocr Pathol. 2022 Mar;33(1):115-154. (PMID: 35294740) Endocr Relat Cancer. 2008 Mar;15(1):337-42. (PMID: 18310299) EJNMMI Res. 2019 Dec 23;9(1):116. (PMID: 31872324) Endocrine. 2017 Sep;57(3):504-511. (PMID: 28664309) World J Surg. 1996 Feb;20(2):168-72. (PMID: 8661813) Am J Surg. 2016 Apr;211(4):778-82. (PMID: 26992358) Endocr Rev. 2021 Mar 15;42(2):133-170. (PMID: 33249439) World J Surg. 2011 Aug;35(8):1879-86. (PMID: 21559999) Int J Cancer. 2021 Mar 1;148(5):1040-1050. (PMID: 32674220) J Natl Compr Canc Netw. 2021 Jul 28;19(7):839-868. (PMID: 34340212) Endocr Relat Cancer. 2023 Jul 11;30(8):. (PMID: 37184955) Eur J Endocrinol. 2013 Jan 17;168(2):185-93. (PMID: 23132699) Gastroenterology. 1999 Jun;116(6):1310-8. (PMID: 10348814) Oncologist. 2021 May;26(5):383-388. (PMID: 33496040) Gastroenterology. 1993 Apr;104(4):994-1006. (PMID: 7681798) Eur J Gastroenterol Hepatol. 2001 Dec;13(12):1449-56. (PMID: 11742193) Clin Nucl Med. 2018 Nov;43(11):802-810. (PMID: 30247209) Gastric Cancer. 2020 Jul;23(4):591-599. (PMID: 32026156) J Surg Res. 2010 Jul;162(1):22-5. (PMID: 20421108) Lancet Oncol. 2008 Jan;9(1):61-72. (PMID: 18177818) Surgery. 2015 Feb;157(2):269-76. (PMID: 25311263) Hepatogastroenterology. 2013 Sep;60(126):1524-9. (PMID: 23933946) Arch Surg. 2001 Jan;136(1):49-54. (PMID: 11146777) J Neuroendocrinol. 2023 Mar;35(3):e13249. (PMID: 36924180) Scand J Gastroenterol. 1988 Sep;23(7):779-87. (PMID: 3227292) World J Gastroenterol. 2014 Jan 7;20(1):118-25. (PMID: 24415864) Neuroendocrinology. 2016;103(2):186-94. (PMID: 26731334) Gastroenterol Rep (Oxf). 2015 Aug;3(3):201-8. (PMID: 25698559) Neuroendocrinology. 2012;95(2):74-87. (PMID: 22262004) BMC Gastroenterol. 2021 May 24;21(1):238. (PMID: 34030644) World J Gastroenterol. 2013 Dec 14;19(46):8703-8. (PMID: 24379589) Neuroendocrinology. 2014;100(2-3):221-7. (PMID: 25358267) Aliment Pharmacol Ther. 2012 Dec;36(11-12):1067-75. (PMID: 23072686) Neuroendocrinology. 2016;103(2):119-24. (PMID: 26784901) J Thorac Oncol. 2015 Sep;10(9):1240-1242. (PMID: 26291007) Endosc Int Open. 2020 Jun;8(6):E717-E721. (PMID: 32490154) Br J Surg. 2018 Oct;105(11):1480-1486. (PMID: 29893418) JAMA Netw Open. 2021 Jul 1;4(7):e2114180. (PMID: 34313744) J Cancer Res Clin Oncol. 2020 Aug;146(8):2135-2142. (PMID: 32306127) Ann Surg. 2005 Jul;242(1):64-73. (PMID: 15973103) Oncologist. 2019 Jul;24(7):911-920. (PMID: 30482824) BMC Cancer. 2020 Aug 18;20(1):777. (PMID: 32811471) |
| معلومات مُعتمدة: | K12 CA237806 United States CA NCI NIH HHS; UL1 TR002378 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: GNET; Gastric neuroendocrine; Gastrinoma; High-grade; NET; Neuroendocrine carcinoma |
| المشرفين على المادة: | 0 (Gastrins) |
| تواريخ الأحداث: | Date Created: 20231207 Date Completed: 20240208 Latest Revision: 20240312 |
| رمز التحديث: | 20240313 |
| مُعرف محوري في PubMed: | PMC10922891 |
| DOI: | 10.1245/s10434-023-14712-9 |
| PMID: | 38062290 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-4681 |
|---|---|
| DOI: | 10.1245/s10434-023-14712-9 |